Aclaris Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 3.97 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 615.29M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational...